Melanie Thompson et al.
AIDS (London, England), 30(6), 869-878 (2015-12-05)
To compare the efficacy, safety, and anti-inflammatory effects of cenicriviroc (CVC), an oral, once-daily C-C chemokine receptor types 5 and 2 antagonist, with those of efavirenz (EFV) in treatment-naive, HIV-1-infected adults. A 48-week, randomized, double-blind, double-dummy phase 2b trial at